New fiducial marker system for cancer treatment
An Ex-Vivo Human Model Study for Proof of Concept, Usability, Reproducibility, Radio-Opacity and Marker Retention
This study is testing a new device that helps doctors place markers more accurately in cancer patients to improve treatment targeting.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre hospitalier de l'Université de Montréal (CHUM) Academic / other |
| Locations | 1 site (Montreal, Quebec) |
| Trial ID | NCT05465161 on ClinicalTrials.gov |
What this trial studies
This study evaluates the STING-MARK Universal Fiducial Marker System, designed to improve the precision of fiducial marker insertion for cancer treatment. The device allows for biopsy prior to insertion and can be delivered through-the-needle to accurately locate tumors for image-guided therapies. The study aims to establish proof of concept by demonstrating the usability, reproducibility, radio-opacity, and retention of the STING-MARK device in various ex vivo organ samples. The research will be conducted on human solid organs removed during surgical procedures at the Centre hospitalier de l'Université de Montréal.
Who should consider this trial
Good fit: Ideal candidates include patients undergoing surgical resection of solid organs or those receiving solid organ transplants.
Not a fit: Patients who are not undergoing surgery or transplantation of solid organs may not benefit from this study.
Why it matters
Potential benefit: If successful, this device could enhance the accuracy of tumor localization, leading to improved outcomes in cancer treatment.
How similar studies have performed: While this approach is innovative, similar studies have not been widely reported, indicating that this may be a novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients undergoing surgical resection of solid organs * Recipients of solid organ transplantation Exclusion Criteria: * None
Where this trial is running
Montreal, Quebec
- Chum — Montreal, Quebec, Canada (Recruiting)
Study contacts
- Principal investigator: Moishe Liberman, MD — Chum
- Study coordinator: Moishe Liberman, MD
- Email: moishe.liberman@umontreal.ca
- Phone: 514-890-8000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.